Skip to main content
OpenTrials
Completed

NCT Number: NCT00116831

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Atherosclerosis Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Pathological Conditions, Anatomical Pathological Conditions, Signs and Symptoms Plaque, Atherosclerotic Vascular Diseases

Age range

30 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

GSK Investigational Site, Capital Federal, Buenos Aires, Argentina

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female between 30 to 80 years of age, inclusive.
  • Established diagnosis of T2DM (based on diagnostic criteria of the American Diabetes Association (ADA), WHO guidelines or local national guidelines).
  • Subjects who are undergoing coronary angiography for evaluation of suspected or previously diagnosed coronary artery disease or who are undergoing PCI.
  • Subjects' prior anti-hyperglycemic diabetic therapy:

Diet and exercise only (drug naïve), with HbA1c >7.0 and £ 10.0%. HbA1c > 6.5 and <= 8.5%.

  • Left ventricular ejection fraction (EF) ³ 40% as assessed by contrast ventriculography (or previously documented in medical notes within one month prior to index procedure by other methods e.g. echocardiography or nuclear study)
  • Female subjects must be postmenopausal (i.e., >6 months without menstrual period), surgically sterile, or using effective contraceptive measures (oral contraceptives, Norplant, Depo-Provera, an intra-uterine device (IUD), a diaphragm with spermicide or a condom with spermicide). Women of childbearing potential must use effective contraceptive measures for at least 1 month prior to visit 1a, and should continue to use the same contraceptive method during the study and for 30 days after discontinuing study medication.
  • Willingness and ability to give informed consent prior to entering the study and available to complete the study.

Exclusion criteria

  • Type 1 diabetes and/or history of diabetic ketoacidosis.
  • Exposure to a TZD or other PPAR-g agonist within the 6 months prior to screening visit.
  • Subjects treated with triple OAD therapy or high dose dual combination OAD therapy [1].
  • Subjects who have required chronic insulin use in the last 6 months (except during pregnancy or acute episodes such as hospitalization, trauma or infection).
  • ST segment elevation myocardial infarction in the last 30 days.
  • Subjects who have a history or are scheduled to receive coronary artery bypass graft surgery (CABG), valve repair or replacement, aneurysmectomy or planned major non-cardiac surgery during the study period.
  • Subjects who have severe cardiac valvular disease
  • Stroke or resuscitated in the past 6 months
  • History of congestive heart failure (NYHA class I - IV)
  • History of significant hypersensitivity or reaction (e.g., difficulty swallowing, difficulty breathing, tachycardia or skin reaction) to any TZD, SU, biguanide or insulin
  • Prior history of severe edema or edema requiring medical treatment.
  • Chronic disease requiring chronic or intermittent treatment with oral, intravenous, or injected corticosteroids (use of topical, inhaled, or nasal corticosteroids is permissible).
  • Recent history or suspicion of current drug abuse or alcohol abuse within the last 6 months.
  • Untreated hypo- or hyperthyroidism
  • A diagnosis of cancer (other than superficial squamous, basal cell skin cancer, or adequately treated cervical carcinoma in situ) in the past 3 years or current treatment for the active cancer.
  • Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests, or electrocardiogram which, in the judgement of the Investigator, would preclude safe completion of the study.
  • Blood pressure: SBP >170 or DBP > 100 mmHg
  • Significant anemia (Hemoglobin < 11 g/dL for males and < 10 g/dL for females).
  • Significant renal disease manifested by serum creatinine (> 1.5mg/dL for males or > 1.4mg/dL for females), or where the use of metformin is contra-indicated.
  • Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST > 2.5 times upper limit of normal (ULN) or bilirubin >2x ULN).
  • History of myopathy or history of elevated creatine kinase (CK) > 3 times upper normal limit.
  • Use of an investigational drug within 30 days or 5 half-lives (whichever is the longer).
  • Women who are lactating, pregnant or planning to become pregnant during the course of the study.
  • Unwillingness or inability to comply with the procedures described in this protocol.

Treatment and study plan

Glipizide

Drug

oral anti-diabetic medication

rosiglitazone maleate

Drug

oral antidiabetic medication

Primary outcomes

  1. Change From Baseline in Percent Atheroma Volume (PAV) to Month 18

    Time frame: Baseline to Month 18

    The primary efficacy endpoint was change in PAV (defined as total atheroma volume divided by total vessel volume x 100) within a 40 mm segment in non-intervened coronary arteries from Baseline to Month 18, based upon Intravascular Ultrasound (IVUS) assessment.

  2. Model Adjusted Change From Baseline in Percent Atheroma Volume (PAV) to Month 18

    Time frame: Baseline to Month 18

    Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD).

Secondary outcomes

  1. Change From Baseline in Atheroma, Vessel, and Lumen Volume to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18

  2. Model Adjusted Change From Baseline in Atheroma Volume to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  3. Model Adjusted Change From Baseline in Lumen Volume to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  4. Model Adjusted Change From Baseline in Vessel Volume to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  5. Change From Baseline in Atheroma, Vessel, and Lumen Area to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18

  6. Model Adjusted Change From Baseline in Atheroma Area to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  7. Model Adjusted Change From Baseline in Lumen Area to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  8. Model Adjusted Change From Baseline in Vessel Area to Month 18

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Model Adjusted Change (MAC) = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  9. Change From Baseline in Normalized Atheroma Volume

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort.

  10. Model Adjusted Change From Baseline in Normalized Atheroma Volume

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same segment (in non-intervened coronary arteries) from Baseline to Month 18. Normalized atheroma volume is defined as mean atheroma area x median segment length in cohort. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  11. Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area

  12. Model Adjusted Change in Atheroma Volume Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  13. Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area

  14. Model Adjusted Change in Atheroma Area Within the 10 mm of the Non-intervened Vessel Segment With the Greatest Atheroma Volume at Baseline

    Time frame: Baseline to Month 18

    IVUS-derived endpoints measured within the same 10 mm segment of non-intervened coronary arteries with the greatest degree of atheroma volume at Baseline, from Baseline to Month 18, including the nominal change in atheroma volume and atheroma area. Model Adjusted Change = Baseline + Region + Sex + Treatment + Cardiac Procedure + Prior OAD Medication.

  15. Model Adjusted Change in Glycated Hemoglobin (HbA1c) From Baseline to Month 18

    Time frame: Baseline to Month 18

    From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior Oral Anti-Hyperglycemic Diabetic Medications(s) (OAD) + cardiac procedure + treatment x visit.

  16. Model Adjusted Change in Fasting Plasma Glucose (FPG) From Baseline to Month 18

    Time frame: Baseline to Month 18

    From repeated measures analysis model: Change = Baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  17. Repeated Measures Analysis of Percent Change in hsCRP From Baseline to Month 18

    Time frame: Baseline to Month 18

    Changes in cardiovascular biomarkers from Baseline to Month 18, such as high sensitivity C-reactive protein (hsCRP) . Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  18. Repeated Measures Analysis of Percent Change in MMP 9 From Baseline to Month 18

    Time frame: Baseline to Month 18

    Changes in cardiovascular biomarkers from Baseline to Month 18, such as matrix metalloproteinase-9 (MMP-9). Repeated measures analysis model: Log(value) - log(baseline) = log(baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  19. Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18

    Time frame: Baseline to Month 18

    It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1)It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Ratio to baseline as %change mean (%) was used as the estimation parameter for both groups.

  20. Model Adjusted Percent Change in Brain Natriuretic Peptide (BNP) From Baseline to Month 18

    Time frame: Baseline to Month 18

    It was measured as ratio to baseline as percentage change based on log-transformed data : 100 x (exp(Mean change on log scale) - 1). Model Adjusted change based on ANCOVA: Log(value) - log(Baseline) = log(Baseline) + sex + region + treatment + prior OAD + cardiac procedure.

  21. Percent Change From Baseline to Month 18 in Total Cholesterol (TC)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  22. Percent Change From Baseline to Month 18 in High Density Lipoprotein Cholesterol (HDL-c)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  23. Percent Change From Baseline to Month 18 in HDL-2

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  24. Percent Change From Baseline to Month 18 in HDL-3

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  25. Percent Change From Baseline to Month 18 in Low Density Lipoprotein Cholesterol (LDL-c)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  26. Percent Change From Baseline to Month 18 in Triglycerides (TG)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  27. Percent Change From Baseline to Month 18 in Free Fatty Acids (FFA)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  28. Percent Change From Baseline to Month 18 in Apoprotein B (apoB)

    Time frame: Baseline to Month 18

    Repeated measures analysis model: Log(value) - log (Baseline) = log(Baseline) + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  29. Change From Baseline to Month 18 in LDL-c Peak Particle Density Measured by LDL Relative Flotation

    Time frame: Baseline to Month 18

    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  30. Change From Baseline to Month 18 in Total Cholesterol/HDL-c Ratio

    Time frame: Baseline to Month 18

    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  31. Change From Baseline to Month 18 in LDL-c/HDL-c Ratio

    Time frame: Baseline to Month 18

    From repeated measures analysis model: Change = baseline + visit + sex + region + treatment + prior OAD + cardiac procedure + treatment x visit.

  32. Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for All-cause Death, Non-fatal MI, Non-fatal Stroke, Coronary Revascularization, or Hospitalization for Recurrent Myocardial Ischemia (MACE Composite 1)

    Time frame: Baseline to Month 21

    This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.

  33. Number of Participants With the Indicated Treatment Emergent Major Cardiovascular Events (MACE) for Cardiovascular Death, Nonfatal MI, or Nonfatal Stroke (MACE Composite 2)

    Time frame: Baseline to Month 21

    This was 1 of 2 MACE composite endpoints and was a secondary efficacy endpoint.

  34. Number of Other Cardiovascular Events

    Time frame: Baseline to Month 21

    This was one of the secondary endpoints of the study.

Sponsors and collaborators

Lead sponsor

GlaxoSmithKline

Industry

Registry information

Official study title

A Phase III, 18 Month, Multicenter, Randomized, Double-Blind, Active-Controlled Clinical Trial to Compare Rosiglitazone Versus Glipizide on the Progression of Atherosclerosis in Subjects With Type 2 Diabetes Mellitus and Cardiovascular Disease (APPROACH)

Important dates

Study start
2005
Primary completion
2008
Study completion
2008
First posted
Jul 1, 2005
Registry last updated
Mar 23, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.